DS5361b + Pembrolizumab
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor
Trial Timeline
Oct 2, 2025 → Dec 3, 2030
NCT ID
NCT07182591About DS5361b + Pembrolizumab
DS5361b + Pembrolizumab is a phase 1 stage product being developed by Daiichi Sankyo for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07182591. Target conditions include Advanced Solid Tumor.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07182591 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumor